BIOTOXTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,690 KRW | +0.18% |
|
+1.79% | -7.63% |
| 2022 | Biotoxtech Co., Ltd.(KOSDAQ:A086040) dropped from S&P Global BMI Index | CI |
| 2021 | Biotoxtech Co., Ltd.(KOSDAQ:A086040) added to S&P Global BMI Index | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 120,777 | 91,417 | 221,835 | 117,384 | 119,140 | 98,113 |
| Enterprise Value (EV) 1 | 126,573 | 98,916 | 217,925 | 116,282 | 137,509 | 118,666 |
| P/E ratio | 33.3 x | -57.8 x | 84.9 x | 18.1 x | 43.8 x | -19.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.71 x | 3.54 x | 8.39 x | 3.44 x | 3.19 x | 3.01 x |
| EV / Revenue | 3.88 x | 3.83 x | 8.25 x | 3.41 x | 3.69 x | 3.64 x |
| EV / EBITDA | 28.2 x | 50.9 x | 101 x | 19.9 x | 50.1 x | -23.7 x |
| EV / FCF | 54.5 x | 61.4 x | 148 x | 71.6 x | -4.84 x | -11 x |
| FCF Yield | 1.83% | 1.63% | 0.68% | 1.4% | -20.7% | -9.07% |
| Price to Book | 3.86 x | 3.03 x | 6.62 x | 2.85 x | 2.69 x | 1.9 x |
| Nbr of stocks (in thousands) | 14,534 | 14,557 | 14,594 | 14,636 | 14,636 | 15,928 |
| Reference price 2 | 8,310 | 6,280 | 15,200 | 8,020 | 8,140 | 6,160 |
| Announcement Date | 3/14/19 | 3/19/20 | 3/18/21 | 3/17/22 | 3/21/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 32,582 | 25,854 | 26,429 | 34,087 | 37,292 | 32,631 |
| EBITDA 1 | 4,494 | 1,942 | 2,168 | 5,829 | 2,745 | -4,998 |
| EBIT 1 | 1,654 | -130.8 | 537.5 | 4,157 | 800 | -8,676 |
| Operating Margin | 5.08% | -0.51% | 2.03% | 12.2% | 2.15% | -26.59% |
| Earnings before Tax (EBT) 1 | 4,576 | -1,722 | 3,245 | 6,770 | -643.9 | -11,833 |
| Net income 1 | 3,624 | -1,582 | 2,614 | 7,114 | 2,725 | -4,878 |
| Net margin | 11.12% | -6.12% | 9.89% | 20.87% | 7.31% | -14.95% |
| EPS 2 | 249.6 | -108.7 | 179.0 | 444.3 | 185.9 | -316.1 |
| Free Cash Flow 1 | 2,322 | 1,611 | 1,475 | 1,624 | -28,440 | -10,757 |
| FCF margin | 7.13% | 6.23% | 5.58% | 4.76% | -76.26% | -32.97% |
| FCF Conversion (EBITDA) | 51.66% | 82.92% | 68% | 27.86% | - | - |
| FCF Conversion (Net income) | 64.06% | - | 56.42% | 22.83% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/14/19 | 3/19/20 | 3/18/21 | 3/17/22 | 3/21/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 5,796 | 7,498 | - | - | 18,369 | 20,553 |
| Net Cash position 1 | - | - | 3,910 | 1,102 | - | - |
| Leverage (Debt/EBITDA) | 1.29 x | 3.86 x | - | - | 6.693 x | -4.113 x |
| Free Cash Flow 1 | 2,322 | 1,611 | 1,475 | 1,624 | -28,440 | -10,757 |
| ROE (net income / shareholders' equity) | 10.4% | -4.8% | 7.23% | 18.3% | 0.15% | -19.3% |
| ROA (Net income/ Total Assets) | 1.68% | -0.13% | 0.54% | 3.37% | 0.46% | -3.98% |
| Assets 1 | 215,509 | 1,192,931 | 481,775 | 211,377 | 589,869 | 122,662 |
| Book Value Per Share 2 | 2,150 | 2,074 | 2,297 | 2,811 | 3,022 | 3,247 |
| Cash Flow per Share 2 | 428.0 | 369.0 | 188.0 | 1,270 | 868.0 | 1,725 |
| Capex 1 | 2,319 | 449 | 1,366 | 7,619 | 30,676 | 4,452 |
| Capex / Sales | 7.12% | 1.74% | 5.17% | 22.35% | 82.26% | 13.64% |
| Announcement Date | 3/14/19 | 3/19/20 | 3/18/21 | 3/17/22 | 3/21/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -7.63% | 67.16M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- A086040 Stock
- Financials Biotoxtech Co., Ltd.
